Epigenetic Regulation of Cell Cycle Control in Colorectal Cancer: Molecular Mechanisms and Therapeutic Perspectives
7 affiliations
- 1Department of Pharmacology, Saveetha Medical College & Hospital, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University, Chennai Tamil Nadu, India
- 2Department of Community Medicine, Apollo Institute of Medical Sciences And Research Chittoor, India
- 3Department of Physiotherapy, Apollo College of Physiotherapy, the Apollo Knowledge Centre, Murukambattu, Chittoor 517127, India
- 4Division of Allied Health Sciences, School of Health Sciences, the Apollo University, Murukambattu, Chittoor, India
- 5Saveetha College of Physiotherapy, Saveetha Institute of Medical and Technical Sciences, Chennai, India
- 6Department of Pharmaceutical Chemistry, Apollo Institute of Pharmaceutical Sciences, The Apollo University, The Apollo Knowledge City Saketa, Chittoor, India
- 7School of Social Sciences, The Apollo University, Chittoor, India
Abstract
Purpose:: Epigenetic dysregulation is increasingly recognized as a fundamental driver of cell cycle checkpoint failure in colorectal cancer. Beyond genetic mutations, epigenetic mechanisms provide a dynamic and potentially reversible layer of control over cyclin-dependent kinase activity and tumor progression. This mechanistic critical review examines how epigenetic alterations reshape cell cycle regulation in colorectal cancer and evaluates their translational relevance.
Methods:: This review adopts a critical mechanistic approach, integrating and interpreting evidence from experimental, translational and clinical studies addressing epigenetic regulation of cell cycle control in colorectal cancer. Rather than following a systematic review framework, the literature was evaluated conceptually to identify dominant mechanisms, areas of convergence and unresolved controversies.
Results:: Evidence indicates that aberrant DNA methylation, histone modifications and chromatin remodeling converge to repress key cyclin-dependent kinase inhibitors including p16INK4a, p21Cip1 and p27Kip1. These epigenetic alterations sustain cyclin–CDK activity thereby promote bypass of G1/S checkpoint control and facilitate uncontrolled proliferation. Importantly, epigenetic heterogeneity across colorectal tumors contributes to variable therapeutic responses and resistance to both conventional and epigenetic-targeted therapies.
Conclusion:: Epigenetic control of cell cycle checkpoints represents a central and therapeutically exploitable mechanism in colorectal cancer. A mechanistic understanding of these regulatory networks highlights opportunities for rational combination strategies and precision-based interventions while underscoring current knowledge gaps that warrant further investigation.
Related
- Epigenetic regulation of immune checkpoint signaling by microbial metabolites: mechanisms, therapeutic potential, and future perspectives
- Crosstalk between PI3K/AKT signaling and epigenetic regulation in hepatocellular carcinoma: molecular mechanisms and therapeutic opportunities
- Epigenetic Mechanisms in Neurodegenerative Diseases: From Genetic Regulation to Therapeutic Potential
- Epigenetic Regulation of Pyroptosis in Kidney Disease: From Molecular Mechanisms to Therapeutic Potential
- Epigenetic regulation of humoral immunity: molecular mechanisms, diseases and therapeutic targets.
BibTeX
@article{srinivasa2026epigenetic,
title = {{Epigenetic Regulation of Cell Cycle Control in Colorectal Cancer: Molecular Mechanisms and Therapeutic Perspectives}},
author = {Srinivasa B and Devika P Jeeragyal and Kiran Velukuri and Amarnath Reganti and Vaheedha S and Vinodhkumar Ramalingam and Rajasekar Sreerama and Neelima Grandhe and Praveen Hoogar},
journal = {Advanced Pharmaceutical Bulletin},
year = {2026},
month = may,
doi = {10.34172/apb.47190},
url = {https://doi.org/10.34172/apb.47190},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Epigenetic Regulation of Cell Cycle Control in Colorectal Cancer: Molecular Mechanisms and Therapeutic Perspectives
AU - Srinivasa B
AU - Devika P Jeeragyal
AU - Kiran Velukuri
AU - Amarnath Reganti
AU - Vaheedha S
AU - Vinodhkumar Ramalingam
AU - Rajasekar Sreerama
AU - Neelima Grandhe
AU - Praveen Hoogar
PY - 2026
DA - 2026/05/23
JO - Advanced Pharmaceutical Bulletin
DO - 10.34172/apb.47190
UR - https://doi.org/10.34172/apb.47190
AB - Purpose:: Epigenetic dysregulation is increasingly recognized as a fundamental driver of cell cycle checkpoint failure in colorectal cancer. Beyond genetic mutations, epigenetic mechanisms provide a dynamic and potentially reversible layer of control over cyclin-dependent kinase activity and tumor progression. This mechanistic critical review examines how epigenetic alterations reshape cell cycle regulation in colorectal cancer and evaluates their translational relevance. Methods:: This review adopts a critical mechanistic approach, integrating and interpreting evidence from experimental, translational and clinical studies addressing epigenetic regulation of cell cycle control in colorectal cancer. Rather than following a systematic review framework, the literature was evaluated conceptually to identify dominant mechanisms, areas of convergence and unresolved controversies. Results:: Evidence indicates that aberrant DNA methylation, histone modifications and chromatin remodeling converge to repress key cyclin-dependent kinase inhibitors including p16INK4a, p21Cip1 and p27Kip1. These epigenetic alterations sustain cyclin–CDK activity thereby promote bypass of G1/S checkpoint control and facilitate uncontrolled proliferation. Importantly, epigenetic heterogeneity across colorectal tumors contributes to variable therapeutic responses and resistance to both conventional and epigenetic-targeted therapies. Conclusion:: Epigenetic control of cell cycle checkpoints represents a central and therapeutically exploitable mechanism in colorectal cancer. A mechanistic understanding of these regulatory networks highlights opportunities for rational combination strategies and precision-based interventions while underscoring current knowledge gaps that warrant further investigation.
SN - 2228-5881
SN - 2251-7308
ER -